Fig. 2.

AML cells show variable sensitivity to the combination of cytarabine and daunorubicin. Bone marrow primary AML cells were cultured on a stromal-feeder layer and then were treated with 4.5 μM cytarabine (AraC)+1.35 μM daunorubicin (DnR) for 24 h. AML cell viability was evaluated using 7-AAD staining and flow cytometry. (A) The cytotoxic effect of AraC+DnR on the overall blast population. The graph shows the percentage of live cells for each sample. (B) Treatment with AraC+DnR leads to enrichment of the CD34⁺/CD38⁻ cell population in the surviving fraction. The graph shows the percentage of the CD34⁺/CD38⁻ cells within the surviving AML cell population in each sample. Different shapes indicate data-points corresponding to different patient samples. (Patients cross-referencing with Table 1: Patient 1 (○), Patient 2 (■), Patient 3 (●), Patient 4 (□)).